Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Infection risk factors and burden in patients treated with T-cell engaging bispecific antibodies for relapsed B-cell lymphoma and multiple myeloma

Blood (2025) 146 (Supplement 1): 2814.

https://doi.org/10.1182/blood-2025-2814

Published: 2025

Journal Articles

A pilot study of nicotinamide riboside supplementation in allogeneic bone marrow transplantation

Ronald Sobecks, Navneet Majhail, Xiaorong Gu, Xuefei Jia, Megan Molnar, John Desamito, Dongxu Jiang, Kacey O'Donnell, Songa Bae, Craig Sauter, Andrew Trunk, Deepa Jagadeesh, Matt Kalaycio, Betty K. Hamilton, Claudio Brunstein, Jaroslaw Maciejewski, Babal Jha

Blood (2025) 146 (Supplement 1): 2437.

https://doi.org/10.1182/blood-2025-2437

Published: 2025

Journal Articles

Real-time interleukin-6 (IL-6) kinetics predict cytokine release syndrome (CRS) in patients receiving chimeric antigen receptor (CAR) T-cell therapy for Relapsed/Refractory B-cell malignancies

Agrima Mian, Rafaella Ferreira De Araujo Litvin, Jessica Colon-Franco, Sujata Patil, Megan Molnar, Allison Winter, Sandra Mazzoni, Robert Dean, Louis Williams, Aaron Gerds, John Molina, Shahzad Raza, Faiz Anwer, Deepa Jagadeesh, Betty K. Hamilton, Claudio Brunstein, Brian Hill, Paolo Caimi

Blood (2025) 146 (Supplement 1): 2397.

https://doi.org/10.1182/blood-2025-2397

Published: 2025

Journal Articles

Unwinding the genomic threads of monoclonal gammopathy of renal significance through ultra-low pass whole genome sequencing

Blood (2025) 146 (Supplement 1): 3970.

https://doi.org/10.1182/blood-2025-3970

Published: 2025

Journal Articles

Melphalan weight-based dosing in overweight and obese patients undergoing autologous transplant for multiple myeloma

Anmol Goyal, Daniel Cancilla, Wei Wei, Danielle Cenin, Faiz Anwer, Claudio Brunstein, Shahzad Raza, Louis Williams, Jack Khouri

Blood (2025) 146 (Supplement 1): 4033.

https://doi.org/10.1182/blood-2025-4033

Published: 2025

Journal Articles

Real-world response and toxicity profiles of sequential bispecific antibody therapies in Relapsed/Refractory multiple myeloma

Agrima Mian, Rafaella Ferreira De Araujo Litvin, Kelsey Pandrangi, Kristina Nasr, Sharan Jhaveri, Mikhaila Rice, Joslyn Rudoni, Louis Williams, Christy Samaras, John Molina, Betty K. Hamilton, Shahzad Raza, Faiz Anwer, Jason Valent, Claudio Brunstein, Brian Hill, Paolo Caimi, Sandra Mazzoni

Blood (2025) 146 (Supplement 1): 6376.

https://doi.org/10.1182/blood-2025-6376

Published: 2025

Journal Articles

Severe neutropenia after treatment with T-cell engaging bispecific antibodies is associated with higher rates of CRS and disease response

Blood (2025) 146 (Supplement 1): 6350.

https://doi.org/10.1182/blood-2025-6350

Published: 2025

Journal Articles

A Phase 1B/2A study of weekly decitabine and venetoclax treatment as maintenance therapy in high-risk myeloid malignancy patients post allogeneic stem cell transplantation

Sophia Balderman, James Ignatz-Hoover, Claudio Brunstein, Yogen Saunthararajah, Ben Tomlinson

Blood (2025) 146 (Supplement 1): 2510.

https://doi.org/10.1182/blood-2025-2510

Published: 2025

Journal Articles

Cardiovascular disease risk scores as predictors of cardiovascular disease and heart failure in allogeneic hematopoietic cell transplant survivors

Victoria Stepanyants, Xuefei Jia, William Liu, Matt Kalaycio, Ronald Sobecks, Claudio Brunstein, Andrew Trunk, Christina Ferraro, Kayla Giannetti, Arianne Clare Agdamag, Betty K. Hamilton

Blood (2025) 146 (Supplement 1): 2488.

https://doi.org/10.1182/blood-2025-2488

Published: 2025

Journal Articles

Trial in progress: Pilot trial of olutasidenib maintenance post allogeneic hematopoietic cell transplantation in patients carrying IDH1 mutation with AML, MDS, or CMML

Abhay Singh, Guido Marcucci, Akriti Jain, Ryotaro Nakamura, Claudio Brunstein, Amandeep Salhotra

Blood (2025) 146 (Supplement 1): 4287.

https://doi.org/10.1182/blood-2025-4287

Published: 2025

Journal Articles

Factors Associated with Platelet Engraftment Following Allogeneic Hematopoietic Cell Transplantation

Andrew D. Trunk, Hong Li, Matt Kalaycio, Ronald Sobecks, Claudio Brunstein, Craig S. Sauter, Betty K. Hamilton

Blood (2024) 144 (Supplement 1): 3488.

https://doi.org/10.1182/blood-2024-204051

Published: 2024

Journal Articles

Effect of Prior Daratumumab Treatment on Hematopoietic Progenitor Cell Mobilization in Newly Diagnosed Multiple Myeloma

Daniel Cancilla, Joseph Farinella, Amanda Inman, Hong Li, Craig S. Sauter, Faiz Anwer, Claudio Brunstein, Shahzad Raza, Louis Williams, Jack Khouri

Blood (2024) 144 (Supplement 1): 7260.

https://doi.org/10.1182/blood-2024-209082

Published: 2024

Journal Articles

Assessment of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplant When Comparing Treatment with and without Post-Transplant Cyclophosphamide

Daniel P. Nurse, Wei Wei, Amanda Burns, Joseph Farinella, Deepa Jagadeesh, Robert M. Dean, Rabi Hanna, Seth J Rotz, Aaron T. Gerds, Claudio Brunstein, Matt Kalaycio, Craig S. Sauter, Betty K. Hamilton, Ronald Sobecks

Blood (2024) 144 (Supplement 1): 7383.

https://doi.org/10.1182/blood-2024-202626

Published: 2024

Journal Articles

Prevalence and Outcomes of Opportunistic Infections in Steroid Refractory Graft Versus Host Disease Patients Treated with Ruxolitinib, Ibrutinib, and Belumosudil

Victoria Stepanyants, Hong Li, Danielle Cenin, Jessi Edwards, Claudio Brunstein, Matt Kalaycio, Ronald Sobecks, Craig S. Sauter, Betty K. Hamilton

Blood (2024) 144 (Supplement 1): 2145.

https://doi.org/10.1182/blood-2024-199329

Published: 2024

Journal Articles

Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702

Blood (2024) 144 (Supplement 1): 695.

https://doi.org/10.1182/blood-2024-200833

Published: 2024

Journal Articles

Day 100 Risk Assessment Tool Predicts 1 Year Survival in Allogeneic Hematopoietic Cell Transplant Patients

Joseph Farinella, Lauren M Granat, Hong Li, Sharon M Caroniti, Pranay S. Hegde, Matt Kalaycio, Ronald Sobecks, Claudio Brunstein, Craig S Sauter, Betty K. Hamilton

Blood (2023) 142 (Supplement 1): 3725.

https://doi.org/10.1182/blood-2023-189629

Published: 2023

Journal Articles

Influence of Pre-Transplant Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation

Ronald Sobecks, Hong Li, Danielle Cenin, Seema Patel, Jesse Edwards, Stephanie Farlow, Amelia Bragg, Rabi Hanna, Seth J Rotz, Deepa Jagadeesh, Aaron T. Gerds, Robert M. Dean, Brad Pohlman, Betty K. Hamilton, Claudio Brunstein, Matt Kalaycio, Craig S Sauter

Blood (2023) 142 (Supplement 1): 3621.

https://doi.org/10.1182/blood-2023-187071

Published: 2023

Journal Articles

Racial Disparity in Hematopoietic Stem Cell Transplant Clinical Trial Recruitment

Akshee Batra, Rohit Singh, Saloni Savani, Diego Adrianzen Herrera, Atulya Aman Khosla, Claudio Brunstein

Blood (2023) 142 (Supplement 1): 3694.

https://doi.org/10.1182/blood-2023-178463

Published: 2023

Journal Articles

Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin Lymphoma and Multiple Myeloma Treated with CAR T-Cell Therapies

Agrima Mian, Danai Dima, Betty K. Hamilton, Allison Winter, Jack Khouri, Louis S. Williams, Shahzad Raza, Deepa Jagadeesh, Aaron T. Gerds, Robert M. Dean, Matt Kalaycio, Claudio Brunstein, Craig S Sauter, Faiz Anwer, Brian T. Hill, Paolo Caimi

Blood (2023) 142 (Supplement 1): 7399.

https://doi.org/10.1182/blood-2023-188712

Published: 2023

Journal Articles

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

Blood (2022) 139 (8): 1177–1183.

https://doi.org/10.1182/blood.2021011532

Published: 2022

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Infection risk factors and burden in patients treated with T-cell engaging bispecific antibodies for relapsed B-cell lymphoma and multiple myeloma

A pilot study of nicotinamide riboside supplementation in allogeneic bone marrow transplantation

Real-time interleukin-6 (IL-6) kinetics predict cytokine release syndrome (CRS) in patients receiving chimeric antigen receptor (CAR) T-cell therapy for Relapsed/Refractory B-cell malignancies

Unwinding the genomic threads of monoclonal gammopathy of renal significance through ultra-low pass whole genome sequencing

Melphalan weight-based dosing in overweight and obese patients undergoing autologous transplant for multiple myeloma

Real-world response and toxicity profiles of sequential bispecific antibody therapies in Relapsed/Refractory multiple myeloma

Severe neutropenia after treatment with T-cell engaging bispecific antibodies is associated with higher rates of CRS and disease response

A Phase 1B/2A study of weekly decitabine and venetoclax treatment as maintenance therapy in high-risk myeloid malignancy patients post allogeneic stem cell transplantation

Cardiovascular disease risk scores as predictors of cardiovascular disease and heart failure in allogeneic hematopoietic cell transplant survivors

Trial in progress: Pilot trial of olutasidenib maintenance post allogeneic hematopoietic cell transplantation in patients carrying IDH1 mutation with AML, MDS, or CMML

Factors Associated with Platelet Engraftment Following Allogeneic Hematopoietic Cell Transplantation

Effect of Prior Daratumumab Treatment on Hematopoietic Progenitor Cell Mobilization in Newly Diagnosed Multiple Myeloma

Assessment of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplant When Comparing Treatment with and without Post-Transplant Cyclophosphamide

Prevalence and Outcomes of Opportunistic Infections in Steroid Refractory Graft Versus Host Disease Patients Treated with Ruxolitinib, Ibrutinib, and Belumosudil

Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702

Day 100 Risk Assessment Tool Predicts 1 Year Survival in Allogeneic Hematopoietic Cell Transplant Patients

Influence of Pre-Transplant Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation

Racial Disparity in Hematopoietic Stem Cell Transplant Clinical Trial Recruitment

Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin Lymphoma and Multiple Myeloma Treated with CAR T-Cell Therapies

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only